WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong
· Delayed Price · Currency is HKD 33.94
+0.24 (0.71%)
Apr 29, 2026, 4:08 PM HKT
WuXi Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 21,790 | 18,675 | 17,034 | 15,269 | 10,290 | Upgrade
|
| Revenue Growth (YoY) | 16.68% | 9.63% | 11.56% | 48.38% | 83.34% | Upgrade
|
| Cost of Revenue | 11,772 | 11,025 | 10,206 | 8,545 | 5,461 | Upgrade
|
| Gross Profit | 10,019 | 7,651 | 6,828 | 6,724 | 4,829 | Upgrade
|
| Selling, General & Admin | 2,313 | 2,147 | 1,789 | 1,433 | 1,001 | Upgrade
|
| Research & Development | 853.37 | 766.44 | 785.82 | 682.82 | 501.58 | Upgrade
|
| Other Operating Expenses | - | - | 23.47 | -1.49 | 24.29 | Upgrade
|
| Operating Expenses | 3,372 | 3,065 | 2,895 | 2,374 | 1,659 | Upgrade
|
| Operating Income | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 | Upgrade
|
| Interest Expense | -143.06 | -157.59 | -158.49 | -64.38 | -39.19 | Upgrade
|
| Interest & Investment Income | 434.65 | 351.54 | 219.18 | 115.79 | 58.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -267.45 | -45.22 | 46.73 | 417.2 | -32.58 | Upgrade
|
| Other Non Operating Income (Expenses) | -459.22 | 191.9 | 173.38 | 159.56 | 171.36 | Upgrade
|
| EBT Excluding Unusual Items | 6,211 | 4,926 | 4,214 | 4,978 | 3,328 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1,045 | -91.72 | 13.83 | 379.44 | 665.44 | Upgrade
|
| Other Unusual Items | - | - | -53.58 | - | - | Upgrade
|
| Pretax Income | 7,257 | 4,834 | 4,174 | 5,358 | 3,993 | Upgrade
|
| Income Tax Expense | 1,524 | 889.03 | 603.18 | 807.87 | 484.54 | Upgrade
|
| Earnings From Continuing Operations | 5,733 | 3,945 | 3,571 | 4,550 | 3,509 | Upgrade
|
| Minority Interest in Earnings | -824.88 | -589.29 | -170.9 | -129.62 | -120.1 | Upgrade
|
| Net Income | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 | Upgrade
|
| Net Income to Common | 4,908 | 3,356 | 3,400 | 4,420 | 3,388 | Upgrade
|
| Net Income Growth | 46.25% | -1.28% | -23.09% | 30.45% | 100.63% | Upgrade
|
| Shares Outstanding (Basic) | 4,027 | 4,082 | 4,164 | 4,173 | 4,174 | Upgrade
|
| Shares Outstanding (Diluted) | 4,176 | 4,227 | 4,349 | 4,376 | 4,422 | Upgrade
|
| Shares Change (YoY) | -1.22% | -2.80% | -0.62% | -1.04% | 5.05% | Upgrade
|
| EPS (Basic) | 1.22 | 0.82 | 0.82 | 1.06 | 0.81 | Upgrade
|
| EPS (Diluted) | 1.16 | 0.78 | 0.77 | 1.01 | 0.77 | Upgrade
|
| EPS Growth | 47.93% | 1.55% | -23.50% | 31.17% | 92.50% | Upgrade
|
| Free Cash Flow | - | 1,288 | 622.14 | -326.72 | -3,077 | Upgrade
|
| Free Cash Flow Per Share | - | 0.30 | 0.14 | -0.07 | -0.70 | Upgrade
|
| Gross Margin | 45.98% | 40.97% | 40.08% | 44.04% | 46.93% | Upgrade
|
| Operating Margin | 30.50% | 24.55% | 23.09% | 28.49% | 30.81% | Upgrade
|
| Profit Margin | 22.53% | 17.97% | 19.96% | 28.95% | 32.93% | Upgrade
|
| Free Cash Flow Margin | - | 6.89% | 3.65% | -2.14% | -29.90% | Upgrade
|
| EBITDA | 7,910 | 5,849 | 4,928 | 5,069 | 3,622 | Upgrade
|
| EBITDA Margin | 36.30% | 31.32% | 28.93% | 33.20% | 35.20% | Upgrade
|
| D&A For EBITDA | 1,263 | 1,263 | 995.46 | 718.63 | 452.24 | Upgrade
|
| EBIT | 6,646 | 4,585 | 3,933 | 4,350 | 3,170 | Upgrade
|
| EBIT Margin | 30.50% | 24.55% | 23.09% | 28.49% | 30.81% | Upgrade
|
| Effective Tax Rate | 21.00% | 18.39% | 14.45% | 15.08% | 12.13% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.